Lantheus Holdings Inc
LNTH73.900USD
-0.510-0.69%
Market hours （ET）Quotes delayed by 15 min
5.11BMarket Cap
20.09P/E TTM
More Details of Lantheus Holdings Inc Company
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. It classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus on cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, and others. Its clinical candidates include LNTH-2404, NAV-4694, and PNT2002, others. Its OCTEVY is a registrational-stage positron emission tomography (PET) diagnostic imaging agent targeting neuroendocrine tumors.
Company Info
Ticker SymbolLNTH
Company nameLantheus Holdings Inc
IPO dateJun 25, 2015
Founded at2007
CEOMr. Brian A. Markison
Number of employees808
Security typeOrdinary Share
Fiscal year-endJun 25
Address331 Treble Cove Road
CityNORTH BILLERICA
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code01862
Phone19786718001
Websitehttps://www.lantheus.com/
Ticker SymbolLNTH
IPO dateJun 25, 2015
Founded at2007
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Mary Anne Heino
Ms. Mary Anne Heino
Chairman of the Board
Chairman of the Board
584.72K
-4.27%
Mr. Brian A. Markison
Mr. Brian A. Markison
Chief Executive Officer, Director
Chief Executive Officer, Director
232.42K
+35.31%
Ms. Amanda Morgan
Ms. Amanda Morgan
Chief Commercial Officer
Chief Commercial Officer
39.58K
+55.76%
Dr. Jean-Claude Provost, M.D.
Dr. Jean-Claude Provost, M.D.
Chief Scientific Officer
Chief Scientific Officer
38.84K
-31.55%
Dr. James H. (Jim) Thrall
Dr. James H. (Jim) Thrall
Independent Director
Independent Director
35.74K
+7.64%
Ms. Julie H. Mchugh
Ms. Julie H. Mchugh
Lead Independent Director
Lead Independent Director
25.96K
-16.67%
Dr. Gerard Ber, Ph.D.
Dr. Gerard Ber, Ph.D.
Independent Director
Independent Director
23.36K
+10.09%
Ms. Minnie Baylor-Henry, J.D.
Ms. Minnie Baylor-Henry, J.D.
Independent Director
Independent Director
9.90K
+34.47%
Dr. Phuong Khanh (P. K.) Morrow, M.D.
Dr. Phuong Khanh (P. K.) Morrow, M.D.
Independent Director
Independent Director
3.10K
+450.62%
Mr. Samuel R. (Sam) Leno
Mr. Samuel R. (Sam) Leno
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Mary Anne Heino
Ms. Mary Anne Heino
Chairman of the Board
Chairman of the Board
584.72K
-4.27%
Mr. Brian A. Markison
Mr. Brian A. Markison
Chief Executive Officer, Director
Chief Executive Officer, Director
232.42K
+35.31%
Ms. Amanda Morgan
Ms. Amanda Morgan
Chief Commercial Officer
Chief Commercial Officer
39.58K
+55.76%
Dr. Jean-Claude Provost, M.D.
Dr. Jean-Claude Provost, M.D.
Chief Scientific Officer
Chief Scientific Officer
38.84K
-31.55%
Dr. James H. (Jim) Thrall
Dr. James H. (Jim) Thrall
Independent Director
Independent Director
35.74K
+7.64%
Ms. Julie H. Mchugh
Ms. Julie H. Mchugh
Lead Independent Director
Lead Independent Director
25.96K
-16.67%
Revenue Breakdown
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
PYLARIFY
257.65M
0.00%
DEFINITY
79.21M
0.00%
TechneLite
19.71M
0.00%
Strategic partnerships and other
10.75M
0.00%
Other precision diagnostics
5.44M
0.00%
Radiopharmaceutical oncology
0.00
0.00%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
PYLARIFY
257.65M
0.00%
DEFINITY
79.21M
0.00%
TechneLite
19.71M
0.00%
Strategic partnerships and other
10.75M
0.00%
Other precision diagnostics
5.44M
0.00%
Radiopharmaceutical oncology
0.00
0.00%
Shareholding Stats
Updated: Wed, May 14
Updated: Wed, May 14
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
11.27%
The Vanguard Group, Inc.
10.10%
Janus Henderson Investors
9.05%
Farallon Capital Management, L.L.C.
8.71%
State Street Global Advisors (US)
3.81%
Other
57.07%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
11.27%
The Vanguard Group, Inc.
10.10%
Janus Henderson Investors
9.05%
Farallon Capital Management, L.L.C.
8.71%
State Street Global Advisors (US)
3.81%
Other
57.07%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
53.47%
Investment Advisor
43.79%
Hedge Fund
11.55%
Research Firm
3.19%
Individual Investor
2.27%
Pension Fund
1.94%
Bank and Trust
1.35%
Sovereign Wealth Fund
0.57%
Family Office
0.09%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
1027
81.92M
118.40%
-3.35M
2025Q1
1066
83.20M
120.27%
-2.89M
2024Q4
1033
78.65M
114.86%
-4.64M
2024Q3
1003
73.69M
106.06%
-7.92M
2024Q2
959
71.82M
103.63%
-10.29M
2024Q1
912
71.21M
103.87%
-11.25M
2023Q4
868
73.50M
107.32%
-9.24M
2023Q3
828
74.80M
109.31%
-3.81M
2023Q2
790
72.85M
106.61%
-3.94M
2023Q1
733
71.94M
105.47%
-6.73M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
7.79M
11.27%
+17.69K
+0.23%
Mar 31, 2025
The Vanguard Group, Inc.
6.99M
10.1%
-242.63K
-3.36%
Mar 31, 2025
Janus Henderson Investors
6.26M
9.05%
-252.58K
-3.88%
May 30, 2025
Farallon Capital Management, L.L.C.
6.02M
8.71%
+707.00K
+13.30%
Mar 31, 2025
State Street Global Advisors (US)
2.64M
3.81%
-4.26K
-0.16%
Mar 31, 2025
Fidelity Management & Research Company LLC
2.17M
3.14%
+148.84K
+7.36%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.78M
2.57%
+94.57K
+5.62%
Mar 31, 2025
Westfield Capital Management Company, L.P.
1.59M
2.3%
+34.05K
+2.19%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
1.41M
2.04%
-96.91K
-6.42%
Mar 31, 2025
Reinhart Partners, LLC
1.21M
1.74%
-160.93K
-11.77%
Mar 31, 2025
View more
Related ETFs
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Name
Proportion
Harbor Health Care ETF
2.88%
Invesco S&P MidCap 400 GARP ETF
2.64%
Invesco Dorsey Wright Healthcare Momentum ETF
2.28%
SPDR S&P Health Care Equipment ETF
1.83%
Fidelity Stocks for Inflation ETF
1.32%
Janus Henderson US Sustainable Equity ETF
1.26%
Invesco S&P MidCap 400 Pure Growth ETF
1.06%
First Trust Small Cap US Equity Select ETF
1%
Astoria US Quality Kings ETF
0.78%
VictoryShares Free Cash Flow Growth ETF
0.74%
View more
Harbor Health Care ETF
Proportion2.88%
Invesco S&P MidCap 400 GARP ETF
Proportion2.64%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion2.28%
SPDR S&P Health Care Equipment ETF
Proportion1.83%
Fidelity Stocks for Inflation ETF
Proportion1.32%
Janus Henderson US Sustainable Equity ETF
Proportion1.26%
Invesco S&P MidCap 400 Pure Growth ETF
Proportion1.06%
First Trust Small Cap US Equity Select ETF
Proportion1%
Astoria US Quality Kings ETF
Proportion0.78%
VictoryShares Free Cash Flow Growth ETF
Proportion0.74%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
